Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Regulus Therapeutics stock

RGLS
US75915K2006
A2JB9V

Price

1.50
Today +/-
-0.05
Today %
-3.60 %
P

Regulus Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Regulus Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Regulus Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Regulus Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Regulus Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Regulus Therapeutics Stock Price History

DateRegulus Therapeutics Price
11/14/20241.50 undefined
11/13/20241.56 undefined
11/12/20241.56 undefined
11/11/20241.41 undefined
11/8/20241.47 undefined
11/7/20241.48 undefined
11/6/20241.51 undefined
11/5/20241.49 undefined
11/4/20241.49 undefined
11/1/20241.49 undefined
10/31/20241.46 undefined
10/30/20241.56 undefined
10/29/20241.61 undefined
10/28/20241.50 undefined
10/25/20241.44 undefined
10/24/20241.43 undefined
10/23/20241.46 undefined
10/22/20241.49 undefined
10/21/20241.50 undefined
10/18/20241.57 undefined
10/17/20241.52 undefined

Regulus Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Regulus Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Regulus Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Regulus Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Regulus Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Regulus Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Regulus Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Regulus Therapeutics’s growth potential.

Regulus Therapeutics Revenue, EBIT and net profit per share

DateRegulus Therapeutics RevenueRegulus Therapeutics EBITRegulus Therapeutics Net Income
2029e668 M undefined0 undefined550.93 M undefined
2028e339.25 M undefined222.26 M undefined306.52 M undefined
2027e90.17 M undefined10.25 M undefined60.1 M undefined
2026e0 undefined-67.62 M undefined-80.64 M undefined
2025e0 undefined-56.47 M undefined-67 M undefined
2024e0 undefined-45.22 M undefined-51.53 M undefined
20230 undefined-31.11 M undefined-30.04 M undefined
20220 undefined-28.24 M undefined-28.32 M undefined
20210 undefined-27.82 M undefined-27.81 M undefined
202010.01 M undefined-14.16 M undefined-15.73 M undefined
20196.83 M undefined-16.83 M undefined-18.59 M undefined
201870,000 undefined-46.76 M undefined-48.71 M undefined
201770,000 undefined-70.13 M undefined-71.91 M undefined
20161.19 M undefined-81.5 M undefined-81.84 M undefined
201520.76 M undefined-54.76 M undefined-55.75 M undefined
20147.67 M undefined-44.91 M undefined-56.68 M undefined
201319.57 M undefined-17.8 M undefined-18.67 M undefined
201212.7 M undefined-12.57 M undefined-17.41 M undefined
201113.79 M undefined-7.14 M undefined-7.6 M undefined
20108.6 M undefined-15.5 M undefined-15.56 M undefined

Regulus Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
813121972010061000000090339668
-62.50-7.6958.33-63.16185.71-95.00---66.67-------276.6797.05
--------------------
00000000000000000000
-15-7-17-18-56-55-81-71-48-18-15-27-28-30-51-67-8060306550
--53.33142.865.88211.11-1.7947.27-12.35-32.39-62.50-16.6780.003.707.1470.0031.3719.40-175.00410.0079.74
000.070.320.370.430.440.630.871.733.58.5715.2618.96000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Regulus Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Regulus Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20102011201220132014201520162017201820192020202120222023
                           
54.838.198.1114159.7114.176.160.113.934.131.160.439.223.77
0000.10.3101.70.401.10.5000
00000000000000
00000000000000
0.40.50.83.14.910.29.76.35.35.15.14.954.41
55.238.698.9117.2164.9134.387.566.819.240.336.765.344.228.18
3.53.13.33.83.65.411.89.77.80.90.52.82.62.54
00000000000000
00000000000000
0.911.21.11.21.110.80.50.30.10.10.10.03
00000000000000
0.10.10.111.80.30.30.60.30.50.30.300
4.54.24.65.96.66.813.111.18.61.70.93.22.72.57
59.742.8103.5123.1171.5141.1100.677.927.84237.668.546.930.75
                           
42.742.70000.10.10.1000.10.100.03
0.71.6122.5172.5267.9315.7329.5381.1386.9431.3453509.7516.5534.38
-35.4-43-60.4-79.1-135.8-191.5-273.4-345.9-392.7-411.3-427-454.9-483.2-513.21
0-0.1-0.10-0.2-0.1-0.1-0.1000000
00000000000000
81.26293.4131.9124.256.135.2-5.82026.154.933.321.19
1.30.50.31.22.22.75.85.71.71.30.50.30.20.2
1.7124.36.58.77.96.95.833.43.64.44.59
11.310.910.54.93.11.20.10.12.62.431.32.62.38
00000000000000
0.40.40023.40019.916.614.94.704.51.33
14.712.812.810.435.212.613.832.626.721.611.65.211.78.51
10.810.410.111.30019.8000.104.700
00000000000000
26.218.418.584.34.411107.10.403.61.81.06
3728.828.619.34.34.430.8107.10.508.31.81.06
51.741.641.429.739.51744.642.633.822.111.613.513.59.56
59.742.8103.4123.1171.4141.2100.777.82842.137.768.446.830.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Regulus Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Regulus Therapeutics's financial health and stability.

Assets

Regulus Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Regulus Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Regulus Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Regulus Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20102011201220132014201520162017201820192020202120222023
-15-7-17-18-56-55-81-71-48-18-15-27-28-30
00111122200000
00000000000000
25-90-17-5-1482-3-40000
1289273427161145545
00000001211000
00000000000000
12-15-8-28-39-49-56-58-43-19-12-24-25-26
-20-10-1-100000000
-213-30-40-2921351346000-1514
-193-29-40-2822361446000-1415
00000000000000
00400000-3-2-900-3
100654688704302021415
14070468872043-239953411
500000190040183200
00000000000000
5-1231-2219-21-1-1020-329-360
9.89-15.66-9.87-29.13-40.66-51.22-57.79-59.07-43.29-20.04-12.54-24.38-25.89-27.38
00000000000000

Regulus Therapeutics stock margins

The Regulus Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Regulus Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Regulus Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Regulus Therapeutics's sales revenue. A higher gross margin percentage indicates that the Regulus Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Regulus Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Regulus Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Regulus Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Regulus Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Regulus Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Regulus Therapeutics Margin History

Regulus Therapeutics Gross marginRegulus Therapeutics Profit marginRegulus Therapeutics EBIT marginRegulus Therapeutics Profit margin
2029e0 %0 %82.47 %
2028e0 %65.52 %90.35 %
2027e0 %11.37 %66.65 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %-141.46 %-157.14 %
20190 %-246.41 %-272.18 %
20180 %-66,800 %-69,585.71 %
20170 %-100,185.71 %-102,728.58 %
20160 %-6,848.74 %-6,877.31 %
20150 %-263.78 %-268.55 %
20140 %-585.53 %-738.98 %
20130 %-90.96 %-95.4 %
20120 %-98.98 %-137.09 %
20110 %-51.78 %-55.11 %
20100 %-180.23 %-180.93 %

Regulus Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Regulus Therapeutics earnings per share therefore indicates how much revenue Regulus Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regulus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regulus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regulus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regulus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Regulus Therapeutics Revenue, EBIT and net profit per share

DateRegulus Therapeutics Sales per ShareRegulus Therapeutics EBIT per shareRegulus Therapeutics Earnings per Share
2029e10.2 undefined0 undefined8.42 undefined
2028e5.18 undefined0 undefined4.68 undefined
2027e1.38 undefined0 undefined0.92 undefined
2026e0 undefined0 undefined-1.23 undefined
2025e0 undefined0 undefined-1.02 undefined
2024e0 undefined0 undefined-0.79 undefined
20230 undefined-1.64 undefined-1.58 undefined
20220 undefined-1.85 undefined-1.86 undefined
20210 undefined-3.25 undefined-3.25 undefined
20202.86 undefined-4.05 undefined-4.49 undefined
20193.95 undefined-9.73 undefined-10.75 undefined
20180.08 undefined-53.75 undefined-55.99 undefined
20170.11 undefined-111.32 undefined-114.14 undefined
20162.7 undefined-185.23 undefined-186 undefined
201548.28 undefined-127.35 undefined-129.65 undefined
201420.73 undefined-121.38 undefined-153.19 undefined
201361.16 undefined-55.63 undefined-58.34 undefined
2012181.43 undefined-179.57 undefined-248.71 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined

Regulus Therapeutics business model

Regulus Therapeutics Inc. is a publicly traded biotechnology company specializing in the discovery and development of medicines based on microRNAs (miRNAs). Regulus was founded in 2007 and is headquartered in San Diego, California. Regulus Therapeutics is one of the most popular companies on Eulerpool.com.

Regulus Therapeutics SWOT Analysis

Strengths

Regulus Therapeutics Inc possesses several strengths that contribute to its success in the pharmaceutical industry. These include:

  • Strong Research and Development: Regulus Therapeutics Inc invests significantly in research and development, allowing the company to develop innovative drugs and therapies.
  • Intellectual Property Portfolio: The company holds a large portfolio of patents and intellectual property rights, providing a competitive advantage and potential licensing opportunities.
  • Experienced Management Team: Regulus Therapeutics Inc is led by a team of experienced industry professionals who have a deep understanding of the market and can make strategic decisions.
  • Collaborative Partnerships: The company has established partnerships with other pharmaceutical companies and research institutions, allowing for knowledge sharing and resource pooling.

Despite its strengths, Regulus Therapeutics Inc also faces certain weaknesses that need to be addressed for sustained growth and productivity. These weaknesses include:

  • Financial Dependency: The company heavily relies on external funding sources, which can limit financial flexibility and potentially impact research and development capabilities.
  • Drug Development Challenges: The pharmaceutical industry is highly regulated and faces significant challenges in the development and approval of new drugs, which may lead to delays and increased costs.
  • Limited Product Portfolio: Regulus Therapeutics Inc currently has a limited product portfolio, relying on a few key drugs. This dependency increases the company's vulnerability to market fluctuations and competition.

There are several potential opportunities that Regulus Therapeutics Inc can leverage to further enhance its position in the market. These opportunities include:

  • Expansion of Therapeutic Areas: The company can explore new therapeutic areas to diversify its product portfolio and tap into emerging markets.
  • Advancements in Technology: Rapid advancements in technology, such as gene editing and personalized medicine, present opportunities for Regulus Therapeutics Inc to develop innovative treatments and therapies.
  • Global Market Expansion: The company can target international markets to expand its customer base and increase its revenue streams.

Regulus Therapeutics Inc faces several threats that pose challenges to its overall growth and profitability. These threats include:

  • Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share.
  • Regulatory and Compliance Risks: Stringent regulatory requirements and compliance standards can pose challenges during the drug development and approval process.
  • Market Uncertainty: Factors such as changing healthcare policies, economic conditions, and shifts in customer preferences can create market volatility and impact the company's revenues.

Weaknesses

Despite its strengths, Regulus Therapeutics Inc also faces certain weaknesses that need to be addressed for sustained growth and productivity. These weaknesses include:

  • Financial Dependency: The company heavily relies on external funding sources, which can limit financial flexibility and potentially impact research and development capabilities.
  • Drug Development Challenges: The pharmaceutical industry is highly regulated and faces significant challenges in the development and approval of new drugs, which may lead to delays and increased costs.
  • Limited Product Portfolio: Regulus Therapeutics Inc currently has a limited product portfolio, relying on a few key drugs. This dependency increases the company's vulnerability to market fluctuations and competition.

There are several potential opportunities that Regulus Therapeutics Inc can leverage to further enhance its position in the market. These opportunities include:

  • Expansion of Therapeutic Areas: The company can explore new therapeutic areas to diversify its product portfolio and tap into emerging markets.
  • Advancements in Technology: Rapid advancements in technology, such as gene editing and personalized medicine, present opportunities for Regulus Therapeutics Inc to develop innovative treatments and therapies.
  • Global Market Expansion: The company can target international markets to expand its customer base and increase its revenue streams.

Regulus Therapeutics Inc faces several threats that pose challenges to its overall growth and profitability. These threats include:

  • Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share.
  • Regulatory and Compliance Risks: Stringent regulatory requirements and compliance standards can pose challenges during the drug development and approval process.
  • Market Uncertainty: Factors such as changing healthcare policies, economic conditions, and shifts in customer preferences can create market volatility and impact the company's revenues.

Opportunities

There are several potential opportunities that Regulus Therapeutics Inc can leverage to further enhance its position in the market. These opportunities include:

  • Expansion of Therapeutic Areas: The company can explore new therapeutic areas to diversify its product portfolio and tap into emerging markets.
  • Advancements in Technology: Rapid advancements in technology, such as gene editing and personalized medicine, present opportunities for Regulus Therapeutics Inc to develop innovative treatments and therapies.
  • Global Market Expansion: The company can target international markets to expand its customer base and increase its revenue streams.

Regulus Therapeutics Inc faces several threats that pose challenges to its overall growth and profitability. These threats include:

  • Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share.
  • Regulatory and Compliance Risks: Stringent regulatory requirements and compliance standards can pose challenges during the drug development and approval process.
  • Market Uncertainty: Factors such as changing healthcare policies, economic conditions, and shifts in customer preferences can create market volatility and impact the company's revenues.

Threats

Regulus Therapeutics Inc faces several threats that pose challenges to its overall growth and profitability. These threats include:

  • Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share.
  • Regulatory and Compliance Risks: Stringent regulatory requirements and compliance standards can pose challenges during the drug development and approval process.
  • Market Uncertainty: Factors such as changing healthcare policies, economic conditions, and shifts in customer preferences can create market volatility and impact the company's revenues.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Regulus Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Regulus Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Regulus Therapeutics shares outstanding

The number of shares was Regulus Therapeutics in 2023 — This indicates how many shares 18.96 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regulus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regulus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regulus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regulus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Regulus Therapeutics stock splits

In Regulus Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Regulus Therapeutics.

Regulus Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.17 -0.21  (-21.11 %)2024 Q3
6/30/2024-0.15 -0.17  (-13.64 %)2024 Q2
3/31/2024-0.23 -0.29  (-27.75 %)2024 Q1
12/31/2023-0.4 -0.4  (0.72 %)2023 Q4
9/30/2023-0.4 -0.4  (1.14 %)2023 Q3
6/30/2023-0.42 -0.37  (11.53 %)2023 Q2
3/31/2023-0.45 -0.42  (5.7 %)2023 Q1
12/31/2022-0.52 -0.4  (23.11 %)2022 Q4
9/30/2022-0.5 -0.5  (-0.04 %)2022 Q3
6/30/2022-0.49 -0.5  (-1.07 %)2022 Q2
1
2
3
4
...
5

Regulus Therapeutics shareholders

%
Name
Stocks
Change
Date
19.63136 % Federated Hermes Global Investment Management Corp.12,852,65406/30/2024
9.87903 % New Enterprise Associates (NEA)6,467,80206/30/2024
9.54636 % RA Capital Management, LP6,250,00006/30/2024
7.63709 % Vivo Capital, LLC5,000,00006/30/2024
6.51245 % Octagon Capital Advisors LP4,263,70109/30/2024
6.18736 % The Vanguard Group, Inc.4,050,8633,310,6486/30/2024
5.55102 % BlackRock Institutional Trust Company, N.A.3,634,2553,566,2246/30/2024
4.98330 % Deep Track Capital LP3,262,564-4,0026/30/2024
3.08935 % Fidelity Management & Research Company LLC2,022,600-900,0006/30/2024
3.05483 % Adage Capital Management, L.P.2,000,000-1,679,8546/30/2024
1
2
3
4
5
...
10

Regulus Therapeutics Executives and Management Board

Mr. Joseph Hagan(54)
Regulus Therapeutics Chief Executive Officer, Director (since 2016)
Compensation 1.34 M
Mr. Christopher Aker(62)
Regulus Therapeutics Senior Vice President, General Counsel
Compensation 651,543
Ms. Cris Calsada(53)
Regulus Therapeutics Chief Financial Officer
Compensation 627,619
Dr. Stelios Papadopoulos(74)
Regulus Therapeutics Independent Chairman of the Board
Compensation 102,770
Ms. Kathryn Collier(55)
Regulus Therapeutics Independent Director
Compensation 78,770
1
2
3

Regulus Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals
SupplierCustomer0,820,710,630,820,35-0,20
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals
SupplierCustomer0,660,31-0,27-0,460,410,56
Sanofi Stock
Sanofi
SupplierCustomer0,320,34-0,55-0,70-0,58-0,64
1

Most common questions regarding Regulus Therapeutics

What values and corporate philosophy does Regulus Therapeutics represent?

Regulus Therapeutics Inc represents values of scientific innovation, collaboration, and commitment to improving patients' lives. The company's corporate philosophy revolves around developing breakthrough RNA-based therapeutics to address unmet medical needs. Regulus Therapeutics is focused on leveraging its deep expertise in microRNA and oligonucleotide-based therapeutics to develop innovative treatment options for diseases with limited or no available treatment options. Through its cutting-edge research and dedication to advancing the field of RNA therapeutics, Regulus Therapeutics aims to make a meaningful impact in the lives of patients and create value for its stakeholders.

In which countries and regions is Regulus Therapeutics primarily present?

Regulus Therapeutics Inc primarily operates in the United States, focusing on the development of innovative medicines. With headquarters in California and operations located in San Diego, the company is deeply rooted in the biopharmaceutical industry in the U.S. Regulus Therapeutics Inc primarily operates in the domestic market, continuously working towards advancements in the field of medicine.

What significant milestones has the company Regulus Therapeutics achieved?

Regulus Therapeutics Inc has achieved significant milestones in its journey. The company successfully advanced its promising pipeline, focusing on discovering and developing innovative RNA-targeted therapeutics. Notably, Regulus Therapeutics has advanced multiple programs into clinical development, including RG-101, an investigational therapy for Hepatitis C Virus. In addition, the company has formed strategic collaborations with renowned partners to further strengthen its research and development efforts. Regulus Therapeutics Inc has consistently shown dedication and commitment towards revolutionizing healthcare through RNA-based therapeutics, becoming a leading player in the field.

What is the history and background of the company Regulus Therapeutics?

Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. Founded in 2007, Regulus Therapeutics specializes in the research and development of microRNA therapeutics, which play a crucial role in regulating gene expression. The company has a strong expertise in developing drugs for various diseases, including cancer, fibrosis, and metabolic disorders. Regulus Therapeutics has formed strategic collaborations with major pharmaceutical companies to advance their pipeline and accelerate drug development. With a commitment to improving patient lives, Regulus Therapeutics continues to drive scientific advancements and deliver potential therapeutic solutions.

Who are the main competitors of Regulus Therapeutics in the market?

The main competitors of Regulus Therapeutics Inc in the market include companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals. These companies operate in the field of RNA-targeted therapeutics, similar to Regulus Therapeutics Inc. Competition exists within the industry as these companies strive to develop innovative and effective RNA-based therapies for various diseases.

In which industries is Regulus Therapeutics primarily active?

Regulus Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Regulus Therapeutics?

The business model of Regulus Therapeutics Inc revolves around developing and commercializing innovative medicines based on microRNA technology. Regulus focuses on discovering and developing drugs targeting microRNAs involved in regulating key disease pathways. By leveraging its expertise in this emerging field, the company aims to address unmet medical needs across various therapeutic areas, including fibrosis, immune-inflammatory diseases, and metabolic disorders. Regulus is committed to advancing its pipeline of potential therapeutics and collaborating with partners to deliver novel treatments to patients.

What is the P/E ratio of Regulus Therapeutics 2024?

The Regulus Therapeutics P/E ratio is -0.55.

What is the P/S ratio of Regulus Therapeutics 2024?

The Regulus Therapeutics P/S ratio is 0.

What is the Quality Investing of Regulus Therapeutics?

The Quality Investing for Regulus Therapeutics is 4/10.

What is the revenue of Regulus Therapeutics 2024?

The revenue cannot currently be calculated for Regulus Therapeutics.

How high is the profit of Regulus Therapeutics 2024?

The expected Regulus Therapeutics profit is -51.53 M USD.

What is the business model of Regulus Therapeutics

Regulus Therapeutics Inc. is a biotechnology company focused on the development of therapies for chronic diseases. The company was founded in 2007 in San Diego, California. Regulus Therapeutics Inc. is a subsidiary of Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The business model of Regulus Therapeutics is based on the identification of miRNAs that play a role in the development of diseases and the development of therapies that modulate these miRNAs. The company specializes in chronic diseases of the nervous system, liver, and circulatory system. The company is divided into three divisions: research and development, marketing and sales, and operations. The research department develops therapy options for specific diseases using a proprietary technology platform that allows for the targeted development of drugs against individual miRNAs. An important product of Regulus Therapeutics Inc. is the miR-122 inhibitor RG-101. This is a therapy option for patients with chronic hepatitis C infection (HCV). The product has proven to be effective in clinical trials and is already being marketed in some countries. Additionally, the company is working on developing products for other diseases. Regulus Therapeutics has entered into a licensing agreement with Sanofi to develop therapies for autoimmune diseases and cancer. The marketing and sales department of Regulus Therapeutics Inc. is responsible for selling products to hospitals, doctors, and pharmacies. There is close collaboration with clinicians and scientists to align the products with the needs of patients. The operations department of Regulus Therapeutics Inc. is responsible for the administrative and financial aspects of the company. It ensures that the different departments work together and achieve the company's goals. In summary, the business model of Regulus Therapeutics Inc. is based on the development of therapies for diseases of the nervous system, liver, and circulatory system. miRNAs are modulated specifically to develop drugs that are effective against individual diseases. Regulus Therapeutics works closely with clinicians and scientists in the field of research and development to tailor the products to the needs of patients. The company has already made a name for itself in some countries with the miR-122 inhibitor RG-101 and is actively working on developing products for other diseases.

What is the Regulus Therapeutics dividend?

Regulus Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Regulus Therapeutics pay dividends?

The dividend cannot currently be calculated for Regulus Therapeutics or the company does not pay out a dividend.

What is the Regulus Therapeutics ISIN?

The ISIN of Regulus Therapeutics is US75915K2006.

What is the Regulus Therapeutics WKN?

The WKN of Regulus Therapeutics is A2JB9V.

What is the Regulus Therapeutics ticker?

The ticker of Regulus Therapeutics is RGLS.

How much dividend does Regulus Therapeutics pay?

Over the past 12 months, Regulus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regulus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Regulus Therapeutics?

The current dividend yield of Regulus Therapeutics is .

When does Regulus Therapeutics pay dividends?

Regulus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regulus Therapeutics?

Regulus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Regulus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regulus Therapeutics located?

Regulus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regulus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regulus Therapeutics from 11/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did Regulus Therapeutics pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of Regulus Therapeutics in the year 2023?

In the year 2023, Regulus Therapeutics distributed 0 USD as dividends.

In which currency does Regulus Therapeutics pay out the dividend?

The dividends of Regulus Therapeutics are distributed in USD.

All fundamentals about Regulus Therapeutics

Our stock analysis for Regulus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regulus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.